The Big Pharma Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the worlds leading healthcare companies during 2014.
Using these reports, dealmakers will effectively and efficiently gain insight into the partnering activities of the past year. The report series allows you to view all the partnering and alliances deals announced worldwide.
The initial chapters of this report provide an orientation of 2014’s dealmaking and business activities.
Chapter 1 provides an overview of the trends in dealmaking during 2014 covering trends by deal type, stage of development, technology type and therapeutic indication.
Chapter 2 provides a review of the leading deals during 2014. Deals are listed by headline value, signed by big pharma and big biotech, and most active big pharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 3 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of 2014 deals, as well as contract documents available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 4 provides a comprehensive directory of all partnering deals announced during 2014.
The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), therapy area and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report series also includes numerous tables and figures that illustrate the trends and activities in big pharma partnering and dealmaking during 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of technologies and products during 2014.
Table Of Contents
Big pharma Deals and Alliances of 2014 Executive Summary
Chapter 1 - Trends in dealmaking during 2014
1.1. Big pharma dealmaking activity 1.2. Partnering by deal type 1.3. Partnering by industry sector 1.4. Partnering by stage of development 1.5. Partnering by technology type 1.6. Partnering by therapy area
Chapter 2 - Leading deals during 2014
2.1. Introduction 2.2. Top deals by value during 2014
Chapter 3 - Big pharma deals during 2014
3.1. Introduction 3.2. How to use big pharma partnering deals 3.3. Big pharma partnering company profiles for 2014 Abbott Actavis Actelion Allergan Amgen Aspen Pharmacare Astellas AstraZeneca Baxter International Bayer Biogen Idec Boehringer Ingelheim Bristol-Myers Squibb Celgene CSL Daiichi Sankyo Dainippon Sumitomo Eisai Eli Lilly Endo Pharmaceuticals Forest Laboratories Galderma Gilead Sciences GlaxoSmithKline Grifols Hospira Johnson and Johnson Kyowa Hakko Kirin Lundbeck Menarini Merck and Co Merck KGaA Mitsubishi Tanabe Novartis Novo Nordisk Otsuka Pfizer Purdue Roche Sanofi Servier Shionogi Shire Takeda Teva Valeant Warner Chilcott Watson
Chapter 4 - Partnering deals directory 2014
4.1. Introduction 4.2. Company A-Z 4.3. By deal type 4.4. By stage of development 4.5. By technology type 4.6. By therapy area
About Wildwood Ventures
Current Partnering Current Agreements Current Reports Recent titles from CurrentPartnering Order Form - Reports
Table of figures
Figure 1: Big pharma - top 50 - January to December 2014 Figure 2: Big pharma deal frequency - 2014 Figure 3: Partnering by deal type during 2014 Figure 4: Partnering by industry sector during 2014 Figure 5: Partnering by stage of development during 2014 Figure 6: Partnering by technology type during 2014 Figure 7: Partnering by therapy area during 2014 Figure 8: Top deals by value during 2014